Expert InterviewAZN
Slingshot members are talking to an expert! The topic is:
A Second Opinion: Discussing AstraZeneca and Daiichi Sankyo’s DESTINY trial data presented at ASCO 2023 on Enhertu in patients with HER2 advanced solid tumors
Executed on:Jun 15, 2023 4:00 PM EDT
Call Duration:30 minutes
Expert Profile
ExpertBlinded Expert
Institution: Hummingbird Biotherapeutics
- Medical Oncologist and Chief Medical Officer (part-time) of Hummingbird Biotherapeutics (formerly CMO at ImClone and Stemline Therapeutics).
- Focused on the comprehensive development and registration strategies of cancer therapeutics of all types; integrally involved with the development and registration of more than 12 cancer therapeutics.
- While at Johns Hopkins University School of Medicine, he performed seminal clinical development and pharmacologic studies on paclitaxel, docetaxel, irinotecan, topotecan, among other agents; has published approximately 315 manuscripts in both the nonclinical and clinical research fields.
Interview Goal
On this call we will be discussing the potential of AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in patients with HER2-expressing advanced solid tumors based on results from the DESTINY-PanTumor02 Phase II trial and the DESTINY-CRC02 Phase II trial that was recently presented at ASCO 2023.